Printed From BioPortfolio.com
Novo Nordisk diabetes drug effective, preliminary FDA review finds
09:37 EDT 16 Oct 2017 | Reuters
(Reuters) - Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, a preliminary review by the U.S. Food and Drug Administration concluded, sending the company's shares up 3.4 percent in premarket trading on Monday.
Original Article: Novo Nordisk diabetes drug effective, preliminary FDA review finds
